Quick Answer
aTYR PHARMA INC reported R&D Expense of $60.22 million for fiscal year 2025.
aTYR PHARMA INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $60.22M | +10.8% |
| 2024 | $54.37M | +28.6% |
| 2023 | $42.29M | -1.2% |
| 2022 | $42.81M | +84.0% |
| 2021 | $23.26M | +34.5% |
| 2020 | $17.29M | +23.1% |
| 2019 | $14.05M | -31.1% |
| 2018 | $20.39M | -32.2% |
| 2017 | $30.07M | -29.8% |
| 2016 | $42.85M | +24.2% |
| 2015 | $34.50M | +105.7% |
| 2014 | $16.78M | +21.3% |
| 2013 | $13.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.13M | +49.5% | +43.9% |
| June 30, 2025 | $15.38M | +10.1% | +30.2% |
| March 31, 2025 | $11.81M | -11.6% | -20.2% |
| September 30, 2024 | $14.81M | +43.5% | +6.0% |
| June 30, 2024 | $13.97M | +42.0% | +4.6% |
| March 31, 2024 | $13.36M | +42.5% | +29.5% |
| September 30, 2023 | $10.32M | +4.6% | +4.9% |
| June 30, 2023 | $9.84M | +7.7% | +4.9% |
- aTYR PHARMA INC showed an increase of +10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, aTYR PHARMA INC’s r&d expense has grown by 335.4% (from $13.83 million to $60.22 million).
- The most recent figure is from aTYR PHARMA INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: